Advertisement

Topics

Alnylam Pharmaceuticals, Inc. and The Medicines Company Company Profile

14:44 EST 17th December 2018 | BioPortfolio


News Articles [1356 Associated News Articles listed on BioPortfolio]

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following confere...

Alnylam's gene silencing drug wins FDA approval

Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing tec...

Alnylam Announces Submission Of NDA In Japan For ONPATTRO

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) announced it has submitted a New Drug Application (NDA) to Japan's Pharmaceuticals and Medical Devices Agency for approval of patisiran ...

Alnylam to Webcast R&D Day

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video s...

Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug

A few weeks ago, Alnylam Pharmaceuticals indicated it might seek a speedy FDA approval for what could be the second-ever RNA interference medicine to market. After meeting with regulators, however, th...

With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug

Alnylam Pharmaceuticals was just cleared to market the first-ever RNA interference medicine. The second one may not be that far behind. Alnylam (NASDAQ: ALNY), of Cambridge, MA, said this morning that...

Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

[Updated at 3:25 pm ET, see below] Alnylam Pharmaceuticals made history this afternoon. The FDA has just approved Alnylam’s patisiran (Onpattro), making it the first medicine specifically cleared to...

Alnylam to Webcast Presentation at the 2018 Cantor Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2018 Cantor Glob...

Drugs and Medications [1702 Associated Drugs and Medications listed on BioPortfolio]

Cimetidine [Walgreen Company]

Walgreen Co. Cimetidine 200 Drug Facts

Qsr hand sanitizer [Kay Chemical Company]

Drug Facts

Terbinafine hydrochloride [Aurobindo Pharma Limited]

These highlights do not include all the information needed to use terbinafine hydrochloride safely and effectively. See full prescribing information for terbinafine hydrochloride tablets.Terbinafine H...

Conquest [KAY CHEMICAL CO.]

Drug Facts

Sudogest [H.J. Harkins Company, Inc.]

SudoGestNasal Decongestant

PubMed Articles [392 Associated PubMed Articles listed on BioPortfolio]

What to Know About Medicines With New Active Ingredients Approved in FY 2016 / 2016 in Japan and EU: A Brief Comparison of New Medicines Approved in Japan and the EU in 2016.

The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and the European Medicines Agency (EMA) have a long-standing experience of reviews of new medicines, and they meet their target pre-marke...

Does consumer medicines interest reflect medicines use? An Australian observational study comparing medicines call center queries with medicines use.

Consumers have questions about their medication but the nature of these concerns and how they reflect medication use is unknown.

Alnylam launches era of RNAi drugs.

Characteristics of Occupational Injuries in a Pharmaceutical Company in Iran.

To prioritize occupational hazards in a Pharmaceutical Company in Iran using the analytical hierarchy process (AHP).

Impact of Pharmaceuticals on the Environment: Risk Assessment Using QSAR Modeling Approach.

An extensive use of pharmaceuticals and the widespread practices of their erroneous disposal measures have made these products contaminants of emerging concern (CEC). Especially, active pharmaceutical...

Clinical Trials [754 Associated Clinical Trials listed on BioPortfolio]

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Buspirone Hydrochloride 30mg Tablets, Fasting

This study will compare the relative bioavailability (rate and extent of absorption) of 30 mg Buspirone Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 30 mg BU...

To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg

To demonstrate the relative bioavailability of Alprazolam tablets, 1 mg.

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study

To determine single-dose oral bioequivalence of Minocycline HCl Extended Release Tablets 135 mg manufactured by Amneal Pharmaceuticals Co.(I)Pvt. Ltd., India and SOLODYN® (minocycline h...

Companies [3285 Associated Companies listed on BioPortfolio]

Alnylam Pharmaceuticals, Inc. and The Medicines Company

The Medicines Company and Alnylam Pharmaceuticals, Inc.

The Medicines Company is a biopharmaceutical company driven by an overriding purpose – to save lives, alleviate suffering and contribute to the economics of healthcare. The C...

Alnylam Europe AG

Alnylam ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika auf Basis der RNA-Interferenz (RNAi) entwickelt und hierbei eine führende Position inne hat. Die RNAi stellt einen Durchbru...

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery ...

Ligand Pharmaceuticals Incorporated and The Medicines Company

The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise m...

More Information about "Alnylam Pharmaceuticals, Inc. and The Medicines Company" on BioPortfolio

We have published hundreds of Alnylam Pharmaceuticals, Inc. and The Medicines Company news stories on BioPortfolio along with dozens of Alnylam Pharmaceuticals, Inc. and The Medicines Company Clinical Trials and PubMed Articles about Alnylam Pharmaceuticals, Inc. and The Medicines Company for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alnylam Pharmaceuticals, Inc. and The Medicines Company Companies in our database. You can also find out about relevant Alnylam Pharmaceuticals, Inc. and The Medicines Company Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record